by Richard Daverman, PhD and Henry Ye
December 14, 2012 -- Sinopharm (China National Pharmaceutical Group) and China Development Bank recently signed a 40 billion RMB ($6.4 billion) agreement that will help Sinopharm – and China’s pharma industry as a whole – develop on many fronts. CDB will supply the investment in a combination of investment, loans, debt, rent and other financial services. With the new capital, Sinopharm will seek to advance its R&D and manufacturing, while it also internationalizes the pharma industry. More details....
